2020
Central Nervous System Safety During Brief Analytic Treatment Interruption of Antiretroviral Therapy Within 4 Human Immunodeficiency Virus Remission Trials: An Observational Study in Acutely Treated People Living With Human Immunodeficiency Virus
Hellmuth J, Muccini C, Colby DJ, Kroon E, de Souza M, Crowell TA, Chan P, Sacdalan C, Intasan J, Benjapornpong K, Tipsuk S, Puttamaswin S, Chomchey N, Valcour V, Sarnecki M, Tomaka F, Krebs SJ, Slike BM, Jagodzinski LL, Dumrongpisutikul N, Sailasuta N, Samboju V, Michael NL, Robb ML, Vasan S, Ananworanich J, Phanuphak P, Phanuphak N, Paul R, Spudich S. Central Nervous System Safety During Brief Analytic Treatment Interruption of Antiretroviral Therapy Within 4 Human Immunodeficiency Virus Remission Trials: An Observational Study in Acutely Treated People Living With Human Immunodeficiency Virus. Clinical Infectious Diseases 2020, 73: e1885-e1892. PMID: 32916708, PMCID: PMC8492357, DOI: 10.1093/cid/ciaa1344.Peer-Reviewed Original ResearchConceptsAnalytic treatment interruptionHuman immunodeficiency virusAntiretroviral therapyCentral nervous systemRemission trialsDiffusion tensor imagingTreatment interruptionMedian timeImmunodeficiency virusCentral nervous system safetyCSF HIV-1 RNAAdverse CNS effectsAcute HIV infectionImmune activation markersPlasma viral loadHIV-1 RNAMedian participant ageCerebrospinal fluid samplingCognitive performanceHIV remission trialsBrain diffusion tensor imagingMagnetic resonance spectroscopyART resumptionCNS safetyMild worsening
2014
Cerebral metabolite changes prior to and after antiretroviral therapy in primary HIV infection
Young AC, Yiannoutsos CT, Hegde M, Lee E, Peterson J, Walter R, Price RW, Meyerhoff DJ, Spudich S. Cerebral metabolite changes prior to and after antiretroviral therapy in primary HIV infection. Neurology 2014, 83: 1592-1600. PMID: 25261502, PMCID: PMC4223087, DOI: 10.1212/wnl.0000000000000932.Peer-Reviewed Original ResearchConceptsPrimary HIV infectionParietal gray matterInitiation of ARTMI/CrFrontal white matterAntiretroviral therapyGlu/CrCho/CrHIV infectionBasal gangliaWhite matterGray matterN-acetylaspartateT proton magnetic resonance spectroscopyCerebral metabolite changesEarly ART initiationTreatment-naive participantsEarly antiretroviral therapyLevels of glutamateNAA/CrProton magnetic resonance spectroscopyCholine-containing metabolitesMagnetic resonance spectroscopyART initiationHigh-field magnetic resonance spectroscopy
2012
Change in Brain Magnetic Resonance Spectroscopy after Treatment during Acute HIV Infection
Sailasuta N, Ross W, Ananworanich J, Chalermchai T, DeGruttola V, Lerdlum S, Pothisri M, Busovaca E, Ratto-Kim S, Jagodzinski L, Spudich S, Michael N, Kim JH, Valcour V, Phanuphak N, Teeratakulpisarn N, Fletcher J, Suttichom D, Pinyakorn S, Rattanamanee S, Chomchey N, Mangum P, Ubolyam S, Suwanwela N, Chaisinanunkul N, Suthiponpaisan U, Sutthapas C, deSouza M, Ngauy V, Trichavaroj R, Akapirat S, Marovich M, Wendelken L, Busovaca E, Liu C, Mun E, Miller B. Change in Brain Magnetic Resonance Spectroscopy after Treatment during Acute HIV Infection. PLOS ONE 2012, 7: e49272. PMID: 23229129, PMCID: PMC3500278, DOI: 10.1371/journal.pone.0049272.Peer-Reviewed Original ResearchConceptsOccipital gray matterAntiretroviral therapyHIV infectionFrontal gray matterFrontal white matterN-acetyl aspartateBasal gangliaControl subjectsGray matterHIV-negative control subjectsInitiation of ARTSingle-voxel proton magnetic resonance spectroscopyBrain magnetic resonance spectroscopyAcute HIV infectionEarly antiretroviral therapyBrain metabolite levelsNegative control subjectsProton magnetic resonance spectroscopyMagnetic resonance spectroscopyHIV subjectsBrain inflammationNeuronal injuryHIV casesCNS injuryCellular inflammation